Coagulation factor replacement

This page covers all Coagulation factor replacement drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Factor IX (coagulation factor IX), Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site, Coagulation Factor VIII (antihemophilic factor).

Targets

Factor IX (coagulation factor IX) · Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site · Coagulation Factor VIII (antihemophilic factor) · Factor VIII (coagulation cascade cofactor) · Protein C · Factor VIII

Marketed (3)

• Factor IX recovery · Wyeth is now a wholly owned subsidiary of Pfizer · Hematology
  Factor IX recovery refers to the measurement of how much functional Factor IX (a blood clotting protein) is present in the bloodstream after administration of a Factor IX replacement product.
• von Willebrand factor · National Center for Research Resources (NCRR) · Hematology
  Von Willebrand factor (vWF) is a blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for clotting factor VIII.
• Coagulation Factor VIII · Beijing Children's Hospital · Hematology
  Coagulation Factor VIII replaces deficient or dysfunctional clotting factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation.

Phase 3 pipeline (1)

• FVIII (PK subgroup only) · Bioverativ Therapeutics Inc. · Hematology
  FVIII is a recombinant coagulation factor VIII that replaces deficient or dysfunctional clotting factor to restore hemostasis in hemophilia A patients.

Phase 2 pipeline (2)

• Freeze-dried Human Protein C Concentrate · Takeda · Cardiovascular
  Freeze-dried Human Protein C Concentrate works by replacing a clotting factor in the blood to prevent excessive clotting.
• FVIII Replacement · Hoffmann-La Roche · Rare Disease
  Recombinant FVIII replacement to correct FVIII deficiency